Oral Medication for MS

This six-month study is evaluating the patient satisfaction and physician assessment when a change is made from Previous Disease Modifying Therapy (DMT) to Fingolimod (Gilenya) without a washout period.

Major Inclusion/Exclusion

  • Ages 18-65 yrs.
  • Patients must have Relapsing Remitting or Secondary Progressive MS
  • Must have been on a DMT continuously for at least the last six months